23 August 2024 in Nature Communications
Depression is associated with dysregulated circadian rhythms, but the role of intrinsic clocks in mood-controlling brain regions remains poorly understood. We found increased circadian negative loop and decreased positive clock regulators expression in the medial prefrontal cortex (mPFC) of a mouse model of depression, and a subsequent clock countermodulation by the rapid antidepressant ketamine. Selective Bmal1KO in CaMK2a excitatory neurons revealed that the functional mPFC clock is an essential factor for the development of a depression-like phenotype and ketamine effects. Per2 silencing in mPFC produced antidepressant-like effects, while REV-ERB agonism enhanced the depression-like phenotype and suppressed ketamine action. Pharmacological potentiation of clock positive modulator ROR elicited antidepressant-like effects, upregulating plasticity protein Homer1a, synaptic AMPA receptors expression and plasticity-related slow wave activity specifically in the mPFC. Our data demonstrate a critical role for mPFC molecular clock in regulating depression-like behavior and the therapeutic potential of clock pharmacological manipulations influencing glutamatergic-dependent plasticity.
26 November 2025 in Nature Communications
Ketamine is the first glutamatergic agent in clinical use for major depression, but its primary target remains unclear. Further research is needed to develop more specific interventions with fewer side effects. Ketamine is a noncompetitive antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor. Here, we show that ketamine preferentially targets GluN2D-containing NMDA receptors on interneurons, and that selective GluN2D antagonism is sufficient to produce rapid antidepressant-like effects. We use ketamine, the selective GluN2C/D inhibitor NAB-14, Grin2d -siRNA and chemogenetic approaches in hippocampal slices and in vivo mice. We find that GluN2D antagonism inhibits NMDAR currents in interneurons but not pyramidal cells, and that GluN2D-mediated recruitment of GABAergic interneurons controls inhibitory circuits regulating hippocampal activity and plasticity. In a mouse model of depression, GluN2D inhibition recovers excitation-inhibition balance, restores plasticity, and mimics antidepressant-like actions of ketamine with fewer side effects. These findings identify GluN2D as a highly specific target for novel antidepressant therapy.
29 September 2025 in Molecular Psychiatry
Disruptions in sleep, circadian rhythms, and neural plasticity are closely linked to the pathophysiology and treatment of depression. Acute sleep deprivation (SD) produces rapid but transient antidepressant effects, yet the underlying mechanisms remain poorly understood. Using a mouse model of stress-induced depression, we found altered sleep architecture, impaired sleep homeostasis, and disrupted day-night oscillations of the markers of glutamatergic plasticity - Homer1a and synaptic AMPAR expression in the medial prefrontal cortex (mPFC). These changes were accompanied by a blunted homeostatic response to SD. We further show that SD and ketamine, both rapid-acting antidepressants, exert opposing effects on mPFC circadian gene expression: SD enhances the expression of negative clock loop genes (e.g., Per , Cry ), mirroring stress effects, while ketamine downregulates these same genes. Targeted deletion of the core clock gene Bmal1 in CaMK2a-expressing excitatory neurons of the mPFC disrupted sleep-wake architecture, elevated slow-wave activity, and abolished the behavioral and molecular (Homer1a) response to SD. Additionally, pharmacological activation of the clock repressor REV-ERB suppressed the antidepressant effects of SD. Our results demonstrate that the mPFC molecular clock is essential for the regulation of sleep consolidation and homeostasis, and mediates the effects of SD on behavior.
7 October 2024 in Research Square
Ketamine is the first glutamatergic agent in clinical use for major depression. The underlying mechanism and primary target of ketamine are unknown; further research is urgently needed to develop more specific interventions with fewer side effects and better treatment outcomes for severely affected patients. Ketamine is a noncompetitive antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor, a heterotetramer composed of two GluN1 and two GluN2 subunits. Here, we show that ketamine preferentially targets GluN2D-containing NMDA receptors on interneurons, and that selective GluN2D antagonism alone is sufficient to produce rapid antidepressant effects. We used ketamine, selective GluN2D inhibitors, GRIN2D -siRNA and chemogenetic approaches in hippocampal brain slices and in vivo in mice. We found that GluN2D antagonism inhibited NMDAR currents in interneurons but not in pyramidal cells. GluN2D-mediated recruitment of GABAergic interneurons powerfully controls feedback and feed-forward inhibitory circuits to moderate hippocampal network activity and synaptic plasticity. In a mouse model of depression, GluN2D inhibition recovered synaptic excitation-inhibition balance, reversed long-term potentiation deficits and restored synaptic and AMPAR density toward a naïve state. GluN2D antagonism could fully mimic the cellular and behavioral antidepressant actions of ketamine with fewer side effects in terms of motor coordination and anxiety. These findings identify novel and a highly specific target for drug treatment of major depression.
3 April 2025 in Research Square
The pathophysiology of depression involves multiple biological processes, including circuit dysfunction and impaired neuroplasticity, yet an integrative view that links these processes remains elusive. Here, using a combination of circuit manipulation, electrophysiology, behavior, and fiber photometry, we identify a convergent circuit for antidepressant response and plasticity modulation. We demonstrate that chemogenetic activation of the infralimbic cortex (IL) is sufficient to exert rapid antidepressant effects across multiple behavioral domains in a mouse model of stress-induced depression and exerts top-down control over hippocampal plasticity and processing. We show that IL stimulation enhances structural plasticity, restores long-term potentiation and improves state-dependent network dynamics in the hippocampus (HIP). We identified the nucleus reuniens (RE) as a necessary mediator of these effects. Notably, RE inhibition blocks not only IL stimulation-induced antidepressant response but also the therapeutic and neuroplastic effects of ketamine. Our findings demonstrate that the functional IL → RE → ventral HIP circuit plays a central role in the antidepressant response, linking circuit activity, HIP plasticity, and depressive-like behaviors.